Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects

Maja Solman[1], Sasja Blokzijl-Franke[1,*], Florian Piques[2,3,*], Chuan Yan[4,5,6,7], Qiqi Yang[4,5,6,7], Marion Strullu[2,8], Sarah M. Kamel[1], Pakize Ak[1], Jeroen Bakkers[1,9], David M. Langenau[4,5,6,7], Hélène Cavé[2,3], Jeroen den Hertog[1,10,#]

[1] Hubrecht Institute-KNAW and UMC Utrecht, 3584 CT Utrecht, the Netherlands

[2] INSERM UMR_S1131, Institut de Recherche Saint-Louis, University of Paris, Paris, France

[3] Assistance Publique des Hôpitaux de Paris AP-HP, Hôpital Robert Debré, Département de Génétique, Paris, France

[4] Molecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, United States of America

[5] Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, United States of America

[6] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, United States of America

[7] Harvard Stem Cell Institute, Cambridge, MA 02139, United States of America

[8] Assistance Publique des Hôpitaux de Paris AP-HP, Hôpital Robert Debré, Service d'Onco-Hématologie Pédiatrique, Paris, France

[9] Department of Medical Physiology, Division of Heart and Lungs, UMC Utrecht, 3584 CX Utrecht, the Netherlands

[10] Institute of Biology Leiden, Leiden University, 2333 BE Leiden, The Netherlands

* These authors contributed equally

Jeroen den Hertog, **Address**: Hubrecht Institute-KNAW and UMC Utrecht, 3584 CT Utrecht, the Netherlands, **Telephone**: +31 30 212 1800, **Email:** j.denhertog@hubrecht.eu

Abstract

Gain-of-function mutations in the protein-tyrosine phosphatase SHP2 are the most frequently occurring mutations in sporadic juvenile myelomonocytic leukemia (JMML) and JMML-like myeloproliferative neoplasm (MPN) associated with Noonan syndrome (NS). Hematopoietic stem and progenitor cells (HSPCs) are the disease propagating cells of JMML. Here, we explored transcriptomes of HSPCs with Shp2 mutations derived from JMML patients and a novel NS zebrafish model. In addition to major NS traits, CRISPR/Cas9 knock-in Shp2^{D61G} mutant zebrafish recapitulated a JMML-like MPN phenotype, including myeloid lineage hyperproliferation, *ex vivo* growth of myeloid colonies and *in vivo* transplantability of HSPCs. Single cell mRNA sequencing of HSPCs from Shp2^{D61G} zebrafish embryos and bulk sequencing of HSPCs from JMML patients revealed an overlapping inflammatory gene expression pattern. Strikingly, an anti-inflammatory agent rescued JMML-like MPN in Shp2^{D61G} zebrafish embryos. Our results indicate that a common inflammatory response was triggered in the HSPCs from sporadic JMML patients and syndromic NS zebrafish, which potentiated MPN and may represent a future target for JMML therapies.

Introduction

A broad spectrum of heterozygous germline activating mutations in the tyrosine phosphatase SHP2, encoded by *PTPN11* has been found to cause Noonan syndrome (NS), a dominantly inherited developmental disorder from the RASopathy group affecting 1:1,500 individuals. NS is characterized by a systemic impact on development, most commonly resulting in short stature, congenital heart defects and specific craniofacial characteristics (Rauen, 2013; Tajan et al., 2018). Somatic activating mutations in *PTPN11* are the most common cause of sporadic juvenile myelomonocytic leukemia (JMML), a rare but aggressive myelodysplastic and myeloproliferative neoplasm (MPN) occurring in young children (Caye et al., 2015; Tartaglia et al., 2003). Consistently, children with NS are predisposed to developing neonatal MPN, that either regresses without treatment or rapidly progresses to JMML leading to early death (Kratz et al., 2005; Strullu et al., 2014). Previous studies support the view of a strong endogenous role of germline *PTPN11* mutations in the occurrence of myeloproliferative complications with the existence of high-risk mutations (Mulero-Navarro et al., 2015; Strullu et al., 2014). Given the aggressive nature of JMML and lack of therapies, a better understanding of the elusive JMML(-like MPN) pathophysiology and development of reliable preclinical models are essential.

Several lines of evidence indicate the importance of prenatal hematopoiesis such as the young age window for both NS-associated and sporadic JMML. The prenatal origin of *PTPN11* mutations in sporadic JMML suggests that JMML and NS-associated JMML-like MPN originate from fetal hematopoiesis (Behnert et al., 2021). Studying SHP2-driven JMML(-like MPN) during fetal hematopoiesis is challenging in conditional knock-in mouse models of JMML with *PTPN11* mutations, because mutant SHP2 expression is induced only postnatally (Chan et al., 2009; Xu et al., 2011) or indolent MPN is induced (Tarnawsky et al., 2017, 2018). NS knock-in mice with activating *PTPN11* mutations develop mild MPN only after 5 months of age (Araki et al., 2004, 2009).

Zebrafish (*Danio rerio*) with rapid *ex-utero* development, transparent embryos and conserved blood ontogeny emerged as a unique pediatric leukemia model that enables monitoring of leukemogenesis from its initial stages with high temporal and spatial resolution (de Pater & Trompouki, 2018; Gore et al., 2018). Furthermore, NS-associated features, such as shorter body axis length, craniofacial defects, defective

gastrulation and impaired heart looping, are recapitulated in zebrafish embryos upon transient over-expression of NS-associated protein variants (Bonetti et al., 2014; Jopling et al., 2007; Niihori et al., 2019; Paardekooper Overman et al., 2014; Runtuwene et al., 2011).

To better assess the link between dysregulated SHP2 and myeloproliferation in the context of NS, we developed and characterized a novel genetic zebrafish model of NS with Shp2-D61G mutation, a dominantly inherited NS-associated mutation that is most frequently associated with NS/JMML-like MPN in human patients (Strullu et al., 2014; Tartaglia et al., 2001). Mutant zebrafish developed hematopoietic defects consistent with JMML-like MPN. Transcriptomic comparison of HSPCs obtained from JMML patients with somatic *PTPN11* mutations and HSPCs from mutant zebrafish harboring an NS-associated variant of Shp2, suggested common mechanisms of disease initiation in sporadic and syndromic PTPN11-driven JMML. Both data sets show a similar pro-inflammatory gene expression and an anti-inflammatory agent largely rescued the hematopoietic defects in mutant zebrafish, suggesting inflammation as potential drug target for sporadic and syndromic JMML(-like MPN). Our data show that Shp2-mutant zebrafish convincingly model the human NS-associated MPN thereby providing a valuable preclinical model for development of future therapies.

Results

Shp2^{D61G} mutant zebrafish display typical Noonan syndrome traits

To investigate early hematopoietic defects associated with NS in a vertebrate animal model, we turned to zebrafish, which represents a versatile model to study leukemogenesis and in which it is feasible to introduce mutations at will using CRISPR/Cas9-mediated homology directed repair (Tessadori et al., 2018). NS is a dominant autosomal disorder and 50% of NS patients carry heterozygous mutations in the protein-tyrosine phosphatase SHP2 (*PTPN11*). The zebrafish genome contains two *ptpn11* genes (*ptpn11a* and *ptpn11b*), encoding Shp2a and Shp2b. Shp2a is indispensable during zebrafish development, whereas loss of Shp2b function does not affect development (Bonetti et al., 2014). Certain NS mutations are more frequently associated with NS/JMML-like MPN than others. The D61G substitution in SHP2 is the most frequently occurring (Strullu et al., 2014; Tartaglia et al., 2001). The homology between human SHP2 and zebrafish Shp2a is 91% and the amino acid D61 is located in an absolutely conserved region of the protein (**Figure 1-figure supplement 1A**). Thus, we introduced the D61G mutation in zebrafish Shp2a using CRISPR/Cas9-mediated homology directed repair (**Figure 1-figure supplement 1B**), targeting the *ptpn11a* gene. Sequencing confirmed that the oligonucleotide used for the homology directed repair was incorporated correctly into the genome (**Figure 1A**) and that the introduced mutation did not have a detectable effect on Shp2a protein expression (**Figure 1B**). Prior to phenotypic analyses, the mutant lines were outcrossed twice to ensure that potential background mutations due to the CRISPR/Cas9 approach were removed.

Genotypically, heterozygous Shp2$^{D61G/wt}$ zebrafish mutants correspond to NS patients. Consistently, in 32% of heterozygous Shp2$^{D61G/wt}$ and 45% of homozygous

Shp2$^{D61G/D61G}$ embryos at 5 days post fertilization (dpf) we observed typical Noonan

syndrome traits, such as reduced body axis extension, heart edema and craniofacial

deformities. Based on the extent of the phenotypes, defects were categorized as

normal, mild and severe. (**Figure 1C,D**). The observed phenotypic defects were

mostly mild, but in some cases severe defects were found, including severely

stunted growth, edemas of the heart and jaw, and absence of the swim bladder

(**Figure 1C,D**). A more detailed characterization of the typical NS traits showed that

the body axis length was significantly reduced in Shp2^{D61G} mutant embryos at 5dpf

(**Figure 1E**). Furthermore, imaging of Alcian blue stained cartilage revealed NS-

reminiscent craniofacial defects in 4dpf Shp2^{D61G} mutant embryos, characterized by

broadening of the head (**Figure 1F**), leading to an increased ratio of the width of the

ceratohyal and the distance to Meckel's cartilage (**Figure 1G**). We also assessed the

general morphology and function of the mutant embryonic hearts. Whole-mount *in*

situ hybridization (WISH) with cardiomyocyte (*myl7*), ventricular (*vhmc*) and atrial

(*ahmc*) markers identified no obvious morphological heart defects, such as changes

in heart size or heart looping, as well as heart chamber specification at 3dpf (**Figure**

1-figure supplement 1C). A decrease in heart rate (**Figure 1I**), ejection fraction and

cardiac output (**Figure 1-figure supplement 1D,E**) was detected from the

ventricular kymographs obtained from high speed video recordings (Tessadori et al.,

2012) of the Shp2^{D61G} mutant hearts at 5dpf (**Figure 1H**). Effects on cardiac function

varied from embryo to embryo, which is reminiscent of variable heart defects in

human patients.

The embryos with severe phenotypic defects did not develop a swim bladder

and they did not survive to adulthood. The rest of both Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$

mutant zebrafish grew up normally, their life span was not affected, and they

displayed rather mild defects in adult stages, such as shorter body axis (**Figure 1J**),

with markedly reduced length observed from the embryonic stage of 5dpf until the

fully developed adults (**Figure 1K**). In 10% of Shp2^{D61G} mutants the phenotypes

were more severe, with markedly reduced body axis length compared to their

siblings, skinny appearance and with overall redness, especially in the head and gill

region (**Figure 1J**), which is not described in human NS patients and hence, may not

be related to NS.

Taken together, the NS Shp2^{D61G} mutant zebrafish we established

phenocopied several of the typical NS traits, such as stunted growth, craniofacial

defects, and heart defects. Similar to differences in symptoms observed in individual

human patients, the severity of the defects varied among individual Shp2^{D61G} mutant

zebrafish.

Figure 1. Shp2^{D61G} zebrafish display NS-like traits. (A) Sequencing trace derived from Shp2$^{D61G/D61G}$ zebrafish. Oligonucleotide sequence used to generate the model is underlined. Nucleotide substitutions for D61G mutation (red), silent mutations close to the PAM site (green) and the PAM site (blue) are indicated. **(B)** Immunoblot of Shp2 levels from 5 pooled Shp2a^{wt}Shp2b$^{-/-}$ or Shp2a$^{D61G/D61G}$Shp2b$^{-/-}$ embryos using antibodies for Shp2 and tubulin (loading control). **(C)** Representative images of typical Shp2^{D61G} zebrafish embryonic phenotypes at 5dpf. Blue arrows: jaw, green arrows: heart, red arrows: swim bladder. **(D)** Quantification of phenotypes of Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ embryos scored as in **C** normal, mild and severe. **(E)** Body axis length of Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ embryos at 5dpf. **(F)** Representative images of Alcian blue stained head-cartilage of 4dpf Shp2^{wt} and Shp2$^{D61G/wt}$ embryos. (x) width of ceratohyal, (y) distance to Meckel's cartilage. **(G)** Quantified craniofacial defects (x/y ratio). **(H)** Representative ventricular kymographs derived from high speed video recordings of beating hearts of 5dpf Shp2^{wt} and Shp2$^{D61G/wt}$ embryos. Red dotted lines indicate one heart period. **(I)** Heart rates derived from the ventricular kymographs. **(J)** Representative images of typical Shp2^{D61G} zebrafish adult phenotypes at 24wpf. Red arrows indicate skin redness in the jaw region. Scale bar is 0.5cm. Insets, zoom-in of boxed regions. **(K)** Body axis lengths of 10 Shp2^{wt}, 25 Shp2$^{D61G/wt}$ and 10 Shp2$^{D61G/D61G}$ zebrafish measured weekly between 5dpf and 20wpf of age. **(D,E,G,I)** Measurements originate from three distinct experiments. Number on bars: number of embryos. **(E,G,I,K)** Error bars: standard error of the mean (SEM), *p < 0.05; **p < 0.01, ***p < 0.001, ANOVA complemented by Tukey HSD.

Increased numbers of HSPCs and myeloproliferative defects in Shp2^{D61G}
zebrafish embryos

Next we explored hematopoietic abnormalities in the Shp2^{D61G} zebrafish during embryonic development, corresponding to prenatal hematopoietic ontogeny in human. We were not able to observe any effect of the Shp2^{D61G} mutation on primitive hematopoiesis in embryos at 2dpf using WISH for markers of erythroid progenitors (*gata-1*), myeloid progenitors (*pu.1*) and white blood cells (*l-plastin*) (**Figure 2-figure supplement 1A**). On the other hand, a significant effect of the Shp2-D61G mutation on definitive hematopoiesis was observed at 5dpf (**Figure 2**). First, the number of HSPCs was determined using the Tg(*cd41:GFP, kdrl:mCherry-CAAX*) transgenic line. CD41-GFP positive cells mark HSPCs when the GFP signal is low (CD41-GFP^{low}) and thrombocytes when the GFP signal is high (CD41-GFP^{high}). An increased number of CD41-GFP^{low} HSPCs was observed in the caudal hematopoietic tissue region (CHT, corresponding to the fetal liver in human) and the head kidney (corresponding to the bone marrow in human) of the mutant embryos **(Figure 2A,B)**. Shp2^{D61G} mutation seems to affect both proliferation and apoptosis of HSPCs, evident by an increase in CD41-GFP^{low} cells positive for phosphohistone H3 (pHis3), a marker for late G2 and M phase and a decrease in Acridine orange positive cells in the CHT region, marking apoptotic cells (**Figure 2-figure supplement 1B,C**). We observed an increase of *c-myb* positive cells, marking HSPCs and of *l-plastin* positive cells, marking all white blood cells, in both CHT and head kidney region of the Shp2^{D61G} mutants (**Figure 2C-F**). These latter cells appear not to be lymphocytes, since the size of the *ikaros*-positive thymus, was not affected (**Figure 2-figure supplement 1D,E**). On the other hand, the myeloid lineage was markedly expanded, evident from the increase in the number of mpx-GFP positive neutrophils (**Figure 2G,H**), and mpeg-mCherry positive macrophages (**Figure 2G,I**), in Tg(*mpx:GFP, mpeg:mCherry*) double transgenic mutant embryos. Shp2^{D61G} mutant embryos also displayed a mild decrease in the number of CD41-GFP^{high}-positive thrombocytes, and the number of *β-globin* positive erythrocytes (**Figure 2-figure supplement 1F-H)**. The observed defects in all different blood lineages examined here were stronger in the homozygous Shp2$^{D61G/D61G}$ than heterozygous Shp2$^{D61G/wt}$ embryos, supporting a dosage effect. One of the clinical hallmarks of JMML is the hypersensitivity of myeloid progenitors to GM-CSF. GM-CSF is not

present in zebrafish, but stimulation of HSPCs in *ex vivo* colony forming assays in

semi-solid media with Gcsfa or Gcsfb gives rise to colony-forming unit granulocyte

(CFU-G) and colony-forming unit macrophage (CFU-M) type of colonies, similarly

to GM-CSF stimulation in human, suggesting a compensatory role of Gcsfa/b for the

missing GM-CSF in zebrafish (Oltova et al., 2018; Stachura et al., 2013). Compared

to their wt siblings, colonies developed from the CD41-GFP^{low} cells isolated from the

Shp2$^{D61G/wt}$ zebrafish embryos at 5dpf and exposed to Gcsfa were larger in size and

number, demonstrating an enhanced CFU-G and CFU-M colony forming ability

(**Figure 2J,K**). Finally, we tested whether the observed myeloid expansion was

reconstituted upon transplantation of the WKM cells harvested from Shp2$^{D61G/wt}$

animals in the Tg(*mpx:GFP, mpeg:mCherry*) background into the optically clear

recipient *prkdc-/-* immunodeficient zebrafish (Moore et al., 2016). Animals injected

with 1x10^5 mutant WKM cells (3/5) accumulated GFP- and mCherry- positive cells

near the site of injection starting at 14 days and increasing until 28 days. By contrast,

animals injected with WKM cells from control sibling animals with wt Shp2a (5/5)

lacked any GFP- and mCherry- positive cells (**Figure 2L**).

Our findings suggest that the Shp2^{D61G} mutant zebrafish embryos develop

multilineage hematopoietic defects during the definitive wave of fetal hematopoiesis,

which originates in the HSPCs compartment. The observed defect is reminiscent of

JMML-like MPN in human NS patients.

Figure 2. Shp2^{D61G} mutant zebrafish embryos display JMML-like MPN. (A) Representative images of the CHT region of Shp2^{wt} and Shp2^{D61G} zebrafish embryos in Tg(*cd41:GFP, kdrl:mCherry-CAAX*) background at 5dpf. *cd41:GFP^{low}* cells mark HSPCs and *cd41:GFP^{high}* cells thrombocytes. Grey arrow heads indicate *cd41:GFP^{low}* cells. Scale bar, 20µm. **(B)** The low intensity *cd41:GFP* positive cells in the CHT region were counted. **(C)** WISH of 5dpf Shp2^{wt} and Shp2$^{D61G/wt}$ embryos using *c-myb* specific probe. Head kidney (arrow) and CHT (box) are indicated; zoom-in in insert. Scale bars, 150µm. **(D)** Quantification of *c-myb* WISH. *C-myb* expression in Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ embryos was scored as low, mid and high. **(E)** WISH of 5dpf Shp2^{wt} and Shp2$^{D61G/wt}$ embryos using *l-plastin* specific probe. Head kidney (arrow) and CHT (box) are indicated and zoom-in in insert. Scale bars,150µm. **(F)** Quantification of *l-plastin* expression in Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ embryos scored as low, mid and high. **(G)** Representative images of Shp2^{wt} and Shp2^{D61G} zebrafish embryos in Tg(*mpx:GFP, mpeg:mCherry*) background at 5dpf. *Mpx:*GFP marks neutrophils and *mpeg*:mCherry macrophages. Scale bars,150µm. **(H,I)** Number of *mpx*:GFP and *mpeg*:mCherry positive cells per embryo. **(J)** Representative images of colonies developed from *cd41:GFP^{low}* cells isolated from the CHT of 5dpf Shp2^{wt} and Shp2$^{D61G/wt}$ zebrafish embryos, grown in methylcellulose with zebrafish cytokine Gcsfa for 2 days. Scale bar, 50µm. **(K)** Quantification of number of colonies from **J**, t-test. **(L)** WKM cells harvested from Shp2^{wt} and Shp2^{D61G} zebrafish in the Tg(*mpx:GFP, mpeg:mCherry*) background were injected into the peritoneum of adult *prkdc*-/- zebrafish. Recipients were monitored by fluorescence imaging. **(B,D,F,H,I,K)** Measurements originate from at least three distinct experiments. Number on bars: number of embryos. **(B,H,I,K)** Error bars represent SEM. *p < 0.05, **p<0.01, ***p<0.001. **(B,H,I)** ANOVA complemented by Tukey HSD.

Myeloid bias is established during early differentiation of Shp2^{D61G} HSPCs

In an effort to better understand the pathogenesis mechanisms in the Shp2^{D61G} mutant HSPCs, single cell RNA sequencing was performed using SORT-Seq on CD41-GFP^{low} cells derived from 5dpf Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ zebrafish embryos in the Tg(*cd41*:*GFP*, *kdrl*:*mCherry-CAA*X) transgenic background (**Figure 3A,B**). Unlike in human and mouse, the distinct compartments of HSPCs cannot be isolated, due to lack of antibodies and transgenic lines. Thus, to group cells based on their transcriptional program into specific HSPCs clusters, unsupervised clustering was performed using the RaceID3 package (Herman et al., 2018). Clusters were visualized by *t*-distributed stochastic neighbor embedding (*t*-SNE) and 4 major clusters were further analyzed (**Figure 3C**). Based on the differentially expressed genes and GO term analysis, cells from Cluster 1 were determined to be thrombocyte and erythroid progenitors, Cluster 2 HSC-like HSPCs, Cluster 3 early myeloid progenitors and Cluster 4 monocyte/macrophage progenitors (**Figure 3C, Figure 3-figure supplement 1A, Supplementary file 1**). A small subset of cells in Cluster 4 represented more differentiated neutrophil progenitors (**Figure 3-figure supplement 1B**).

HSPCs of either Shp2^{wt} or mutant Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ genotypes were present in all 4 major clusters, indicating that distinct HSPCs phenotypes were maintained on a gene transcription level. However, the distribution of cells in clusters differed among genotypes. An overrepresentation of mutant Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ cells was observed in the HSC-like HSPCs cluster and monocytes/macrophages progenitors cluster, whereas these were underrepresented in the thrombocyte and erythroid progenitors cluster (**Figure 3D,E**). To validate this observation, we investigated the expression of *pu.1* and *alas2* markers in Shp2^{D61G} embryos of different genotypes by WISH. In the single cell RNA sequencing dataset, expression of *pu.1* and *alas2* was upregulated in the myeloid progenitors and erythroid progenitors, respectively (**Figure 3F,I**). An increased number of *pu.1* positive cells was detected by WISH in 5dpf old Shp2^{D61G} embryos compared to their Shp2^{wt} siblings (**Figure 3G,H**), whereas the number of *alas2* positive cells in Shp2^{D61G} mutants was decreased (**Figure 3J,K**).

Taken together, single cell RNA sequencing suggests that defects during early differentiation of HSPCs to monocyte/macrophage progenitors and

244   erythroid/thrombocyte progenitors initiate the multilineage blood defect observed in

245   Shp2^{D61G} embryos, which recapitulates features of NS-JMML-like MPN.

Figure 3. Single cell RNA sequencing of HSPCs reveals myeloid bias in Shp2^{D61G} embryos. (A) Schematic representation of the experimental procedure. At 5dpf, CHTs from Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ embryos in Tg(*cd41*:*GFP, kdrl:mCherry-CAAX*) background were isolated. Cells were dissociated and separated by FACS, based on *cd41:GFP^{low}* expression, prior to single cell RNA sequencing, as described in the Materials and methods section. **(B)** Number of cells of distinct genotypes used in single cell RNA sequencing analysis. **(C)** Combined tSNE map generated using the cells of all three genotypes (Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$). Single cells from 4 major clusters are marked in dark green, blue, pink and green and their identities based on marker gene expression are indicated. Minor clusters are marked in grey. **(D)** Barplots showing the percentage of cells of Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ genotype in distinct clusters. **(E)** Cells of distinct genotypes Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ are visualized in tSNE maps in red. **(F)** tSNE maps showing log2-transformed read-counts of *pu.1*. **(G)** Representative images of the WISH staining for *pu.1* expression in 5dpf Shp2^{wt} and Shp2^{D61G} zebrafish embryos. Scale bar,100µm. **(H)** Expression of the *pu.1* marker scored as low, mid and high. **(I)** tSNE maps showing log2-transformed read-counts of *alas-2*. **(J)** Representative images of the WISH staining for *alas-2* expression in the tail region of 5dpf Shp2^{wt} and Shp2^{D61G} zebrafish embryos. Scale bar, 100µm. **(K)** Expression of the *alas-2* marker scored as low, mid and high. **(H,K)** Number on bars: number of embryos.

Excessive proinflammatory response in monocyte/macrophage progenitors of Shp2^{D61G} HSPCs

We further analyzed the cluster of monocyte/macrophage progenitors, in which we observed an overrepresentation of mutant Shp2^{D61G} cells **(Figure 4A)**. Functional annotation of the differentially expressed genes and the GO-term enrichment analysis revealed enhanced expression of proinflammatory genes in mutant Shp2^{D61G} cells (**Figure 4A,B, Supplementary file 1**). Interestingly, expression of inflammation-related genes, such as *gcsfa*, *gcsfb*, *il1b*, *irg1* and *nfkbiaa,* was constrained to the cells of mutant Shp2^{D61G} genotype in the monocyte/macrophage progenitors cluster, whereas the monocyte marker *timp2b* was equally expressed by cells of distinct genotypes (**Figure 4B)**.

We next aimed to determine at which point the observed inflammatory program initiated during the differentiation of HSC-like cells into monocyte/macrophage progenitors. We used Monocle trajectory interference to order cells from the four major clusters based on their differentiation state along the pseudo-time. HSC-like cells were located at the start of the progression trajectory and from there, two differentiation routes were determined, one leading to the thrombocyte and erythrocyte progenitors, and the second one leading to the monocyte/macrophage progenitors (**Figure 4C,D**). The route that includes HSC-like cells, early myeloid progenitors and monocyte/macrophage progenitors was then selected (**Figure 4C,D, Figure 4-figure supplement 1A**) and the expression of inflammatory genes in distinct genotypes were computed along it (**Figure 4E, Figure 4-figure supplement 1B**). Expression of the monocyte marker *timp2b* started during early differentiation of monocyte/macrophage progenitors. The level of *timp2b* expression was similar in Shp2^{wt} and Shp2^{D61G} HSPCs Expression of the inflammatory genes, *il1b*, *gcsfa*, *irg1*, *nfkbiaa* and *tnfa* started at a similar pseudo-time as *timp2b* expression, but with a more robust expression in Shp2^{D61G} HSPCs than in Shp2^{wt} HSPCs. Finally, high expression of IL-1β was validated in mutant Tg(*il1b:eGFP*, *mpeg:mCherry*) transgenic embryos *in vivo*. IL-1β-eGFP positive cells were more abundant in the CHT region of Shp2^{D61G} embryos than in wt embryos (**Figure 4F)**.

280   Taken together, Shp2^{D61G} embryos display proinflammatory gene expression
281   in HSPCs, which is initiated during early differentiation of the monocyte/macrophage
282   progenitor cells.
283

Figure 4. Inflammatory response in monocyte/ macrophage progenitors in Shp2^{D61G} embryos.
(A) The monocyte/macrophage progenitors cluster (boxed on the tSNE map on left) was analyzed in detail. log2-transformed sum of read-counts of selected inflammation-related genes from the top 50 differentially expressed genes in the cells of the monocyte/macrophage progenitors cluster, with genotype and number of cells (n) indicated above. **(B)** Violin plots show the expression of specific genes in monocyte/macrophage progenitors of Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ genotypes. NS, not significant, ***p < 0.001, t-test. **(C,D)** Monocle pseudotime trajectory of Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ HSPCs differentiation superimposed on the four clusters and indicated by color in D. A route leading from HSC-like cells to monocyte/macrophage progenitors was selected and its root (R) and end are marked with red circles. **(E)** Pseudotemporal expression dynamics of specific genes along the selected route. The lines represent the smoothened regression of the moving average for Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ genotypes. **(F)** *In vivo* imaging of the CHT region of Shp2^{wt} and Shp2$^{D61G/wt}$ zebrafish embryos in Tg(*il1b:eGFP*, *mpeg:mCherry*) background at 5dpf. Representative images are shown. The dashed line boxed region of CHT is zoom-in in insert. Scale bar is 10μm.

PTPN11 Somatic mutations induce inflammatory response genes in HSPCs of JMML patients.

We hypothesized that activating mutations in Shp2 may trigger an inflammatory response in a similar way in sporadic JMML as we observed in syndromic JMML-like MPN. To investigate this, we performed transcriptomic analysis of the HSPCs compartments derived from bone marrows of sporadic JMML patients with activating mutations in SHP2 (n=5) and age-matched healthy donors (n=7). The SHP2 mutations in JMML HSPCs were distinct among patients and both HSCs and progenitors were included (**Supplementary file 2**). Overall, we identified 1478 differentially expressed genes (DEGs) in HSPCs from JMML patients, compared to the healthy donor HSPCs (**Figure 5A**, **Supplementary file 3**). The functional analysis of DEGs using gene set enrichment analysis (GSEA) was performed to systematically explore hallmark gene signatures specific for JMML HSPCs (**Figure 5B, Supplementary file 4**). Strikingly, altered expression of genes related to inflammation was the most prominent, such as genes involved in TNFα signaling via NFκB. The inflammatory response genes were significantly enriched in JMML HSPCs (**Figure 5B-D**). De-regulation of genes related to proliferation (G2M checkpoint, MYC targets and E2F targets) was evident in JMML HSPCs, suggesting their decreased quiescence (**Figure 5B**).

We next studied whether the inflammatory-related gene signature overlaps between HSPCs from zebrafish NS/JMML-like MPN model and human JMML. GSEA revealed that human orthologs of the top 100 DEGs found in the zebrafish monocyte/macrophage progenitor cells were enriched significantly in patient JMML HSPCs (**Figure 5E**). Some of the top overexpressed inflammation-associated genes in JMML patients, such as TNF and MARCKSL were also overexpressed in NS/JMML-like MPN mutant zebrafish embryos compared to the wt (**Figure 5F,G**). 3D PCA analysis visualized that these zebrafish signature genes were able to clearly segregate HSPCs from JMML patients and healthy donors (**Figure 5H**). These findings suggest that mutant, activated SHP2 triggers proinflammatory gene expression in HSPCs both in sporadic JMML patients and in our zebrafish model of syndromic JMML-like MPN in a similar manner, suggesting a common underlying, endogenously driven process.

Figure 5. Similar molecular signatures in HSPCs from human JMML patients and zebrafish Shp2^{D61G} embryos. (A) Volcano plot of differentially expressed genes of HSPCs derived from bone marrow of JMML patients with *PTPN11* mutations (n=5) and healthy bone marrow (n=7). Underexpressed genes are marked in blue and overexpressed genes are marked in red. *TNFA* expression is highlighted. Green dashed lines indicate the significance level. **(B)** GSEA for the MSigDB's hallmark gene sets in HSPCs from JMML compared to normal human age-matched bone marrow. GSEA plots for TNFA_SIGNALING_VIA_NFKB **(C)**, INFLAMMATORY RESPONSE **(D)**, and the custom Zebrafish signature based on the top 100 human orthologous of genes upregulated in monocyte/macrophage progenitor cluster of zebrafish HSPCs **(E)**. Violin plots show the expression of *TNFA* **(F)** and *MARCKSL* **(G)** in either human wt vs. JMML HSPCs, and zebrafish Shp2^{wt} vs. Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ monocyte/macrophage HSPC progenitors. **p<0.01, ***p < 0.001, t-test. **(H)** PCA for the 100 genes included in the custom zebrafish signature. Green dots represent *PTPN11* mutated JMML, gray ones represent normal human age-matched bone marrow. PC1: 19% of the variance, PC2: 16% of the variance, PC3: 14% of the variance.

Inhibition of the proinflammatory response ameliorates the JMML-like MPN phenotype

To investigate the role of the inflammatory response in the blood defect, we assessed the effect of dexamethasone in Shp2^{D61G} embryos. Dexamethasone is an anti-inflammatory agent, which is known to suppress the inflammatory response in the monocyte/macrophage lineage (Ehrchen et al., 2019; Xie et al., 2021). In parallel, inhibitors of the known Shp2-associated signaling pathways were used, targeting MEK (CI1040) or PI3K (LY294002) (Tajan et al., 2015). Shp2^{D61G} embryos were exposed to inhibitors continuously from 2 to 5 dpf (**Figure 6A**). Both CI1040 and LY294002 led to a robust reduction in expansion of both HSPCs and myeloid lineage in mutant embryos, measured by WISH using markers for *c-myb* and *l-plastin* (**Figure 6B,C**), demonstrating that the NS-associated blood development defect in Shp2^{D61G} embryos was largely caused by overactivation of the RAS-MAPK and PI3K pathways as expected.

To our surprise, dexamethasone reduced *c-myb* and *l-plastin* expression to a similar extent as CI1040 and LY294002 (**Figure 6B,C**), indicating a profound role for the inflammatory response in the pathogenesis of NS-associated blood defects. We then examined whether dexamethasone treatment affected the expanded myeloid lineage in Shp2^{D61G} embryos by determining the number of neutrophils and macrophages, in the Tg(*mpx:GFP, mpeg:mCherry*) double transgenic mutant embryos (**Figure 6D-F**). Upon dexamethasone treatment, the number of *mpx*-GFP and *mpeg*-mCherry positive cells decreased in Shp2^{D61G} embryos to similar levels as observed in Shp2^{wt} embryos, indicating that dexamethasone treatment rescued the expansion of the myeloid lineage in Shp2^{D61G} embryos. Dexamethasone did not significantly alter the number of neutrophils or macrophages in wild type embryos (**Figure 6D-F**). Finally, the expression of proinflammatory genes, such as *tnfa*, *il1b* and *gcsfb* in Shp2^{D61G} embryos was reduced in response to dexamethasone treatment to levels observed in Shp2^{wt} embryos (**Figure 6G**).

Taken together, we observed a proinflammatory phenotype of the macrophage/ monocyte lineage in Shp2^{D61G} mutant zebrafish, which was established early during HSPCs differentiation. The anti-inflammatory agent dexamethasone largely rescued the hematopoietic defects, suggesting that the inflammatory response in Shp2^{D61G} mutant zebrafish had a causal role in the pathogenesis of the NS/JMML-like MPN blood phenotype.

Figure 6. Anti-inflammatory treatment of zebrafish Shp2^{D61G} embryos ameliorates the JMML-like MPN phenotype. (A) Schematic overview of the treatments with MEK inhibitor CI1040, PI3K inhibitor LY294002 and anti-inflammatory corticosteroid dexamethasone. Embryos were continuously treated from 48hpf until 5dpf, when either WISH, confocal imaging or RT-qPCR was performed. **(B,C)** WISH staining for the expression of the *c-myb* and *l-plastin* markers was scored as low, mid and high. Measurements originate from at least three distinct experiments. Number on bars: number of embryos. NS, not significant; *p < 0.05, **p<0.01, ***p<0.001, Chi-squared test. **(D)** Representative images of 5 dpf Shp2^{wt} and Shp2^{D61G} zebrafish embryos in Tg(*mpx:GFP, mpeg:mCherry*) background without and with dexamethasone treatment. Scale bars,150µm. **(E,F)** Number of *mpx*:GFP and *mpeg*:mCherry positive cells per embryo. Number on bars: number of embryos. Error bars represent SEM. **(G)** Expression of *tnfa*, *gcsfb* and *il1b* genes determined by RT-qPCR in Shp2^{wt} and Shp2$^{D61G/D61G}$ zebrafish embryos without and with dexamethasone treatment at 5dpf, normalized to *ef1a* expression. Standard deviation of 4 samples in duplicates for each condition are shown. **(E,F,G)** *p < 0.05, **p<0.01, ***p<0.001. ANOVA complemented by Tukey HSD.

Discussion

To investigate the timing and pathophysiology of mutant SHP2-related myeloproliferative defects, we explored the transcriptomes of HSPCs with activating mutations in SHP2, derived from sporadic JMML patients and syndromic NS/JMML-like MPN zebrafish embryos, respectively. Proinflammatory gene expression was evident both in HSPCs from JMML patients and mutant zebrafish. It should be noted that the type of data is different, bulk sequencing of the human samples and single cell sequencing of the zebrafish material. In addition, the source of the material is distinct, FACS-sorted CD41-GFP^{low} HSPCs from zebrafish embryos and immunophenotypically FACS-sorted postnatal HSCs and progenitors from human. Moreover, genotypically, the samples differed in that the zebrafish carried a single Shp2 mutation (D61G) and the human JMMLs carried distinct activating SHP2 mutations even with additional mutations. Therefore, it is not surprising that the ranking of overexpressed inflammatory genes in HSPCs from mutant zebrafish and human JMML patients was not identical. Nevertheless, the similarity of the proinflammatory signatures revealed by GSEA between these diverging samples is striking.

Already early studies reported high levels of proinflammatory cytokines, such as IL-1β, TNF-α, GM-CSF, in JMML patients plasma (Bagby et al., 1988; Freedman et al., 1992). However, little is known about the cellular origin of the proinflammatory status, its pathophysiological role and therapeutic potential. The inflammatory response may be initiated in a cell autonomous way or in response to signals from the microenvironment. Dong et al. suggested that IL-1β is secreted by differentiated monocytes which get recruited upon secretion of the Chemokine, CCL3, by cells of the bone marrow microenvironment containing activating SHP2 mutations. However, the levels of CCL3 in the bone marrow of four NS patients varied (Dong et al., 2016). Furthermore, a microenvironment-driven inflammatory response would not explain high levels of cytokines in sporadic JMML, where niche cells are not mutated. On the other hand, recent reports indicate that JMML leukemia stem cells are heterogeneous but confined to the HSPCs compartment, defining JMML HSPCs as the origin of the disease (Caye et al., 2019; Louka et al., 2021). The pseudotime analysis of inflammatory genes in zebrafish HSPCs indicated that the initiation of the proinflammatory program happens during early differentiation of HSPCs towards the

monocyte/macrophage progenitor lineage in Shp2^{D61G} embryos. The limited number

of human patients included in our analysis allowed us to establish that the HSPCs

compartment from JMML patients showed an inflammatory response, but not which

lineage. Transcriptomic analysis of individual progenitor lineages from additional

patients will be required to conclude which cell type displayed an inflammatory

response. Our data suggest that proinflammatory reprogramming of the

monocyte/macrophage lineage might be endogenously driven at least in part, and

detailed mechanisms remain to be elucidated in the future.

To our knowledge, the Shp2^{D61G} mutant zebrafish we developed is the first NS

zebrafish model carrying an activating Shp2 mutation at its endogenous locus

generated by CRISPR/Cas9-based knock-in technology. Strikingly, phenotypes

developed by the Shp2^{D61G} zebrafish corroborate closely with the phenotypes

displayed by human NS patients and the existing NS mouse models **(Figure 1)**. Our

model presents an exciting novel tool for deciphering pathogenesis mechanisms of

NS with its complex traits and for finding novel therapies for this as yet poorly

treatable condition.

NS children with D61G mutation have a higher predisposition to develop

JMML(-like MPN), and comparably Shp2^{D61G} zebrafish embryos displayed typical

JMML-like MPN characteristics, such as expansion of the myeloid lineage, increased

sensitivity to gcsfa, mild anemia and thrombocytopenia **(Figure 2)**. Furthermore, the

observed blood defect was transplantable to secondary recipients and the disease

originated in HSPCs, which displayed aberrant proliferation and apoptosis. Given the

importance of fetal hematopoiesis during JMML(-like MPN) development, the

zebrafish Shp2^{D61G} mutant represents a reliable and unique model for JMML-like

MPN, which allows us to study hematopoietic defects caused by mutant Shp2 during

the prenatal development for the first time. Our results suggest that the JMML-like

MPN defect is initiated at the CHT, which is the counterpart of fetal liver in human.

Here we observed expanded HSPCs, which displayed aberrant proliferation and

apoptosis. We further characterized the transcriptomes of HSPCs specifically

originating from the CHT, and studied their response to inhibitor treatments directly

at the CHT. Striking similarities between the patient and zebrafish HSPCs

transcriptomes indicate that the Shp2^{D61G} zebrafish model is an exciting preclinical

model for *in vivo* drug screens at relevant developmental time points, in a high

throughput manner.

The only effective treatment of JMML is allogeneic stem cell transplantation,

which has a high relapse rate of 50%. Hence, there is a great need for other means

of therapeutic intervention. The role of inflammation as one of the drivers in myeloid

leukemogenesis is emerging (Arranz et al., 2017; Craver et al., 2018). Here we

demonstrate that dampening inflammation using the glucocorticoid dexamethasone,

partially rescued the observed blood phenotype in Shp2^{D61G}, suggesting that the

inflammatory response evoked in the cells of myeloid/macrophage lineage was an

important driver of the NS/JMML-like blood defect and might be a potential drug

target for both sporadic and syndromic JMML(-like MPN). To our surprise, targeting

inflammation reversed the blood defect to a similar extent as the MAPK and PI3K

pathway inhibitors, emphasizing not only the crucial role of inflammation during

JMML pathogenesis, but also its strong therapeutic potential. Since anti-

inflammatory therapies are non-invasive and widely available, targeting inflammation

might represent a novel avenue for JMML treatment, either alone or in combination

with other therapies.

In conclusion, we observed striking similarities in expression patterns of

HSPCs from sporadic human JMML patients with an activating SHP2 mutation and

HSPCs from an engineered zebrafish model with an activating NS-associated

mutation in Shp2. Particularly genes associated with the inflammatory response

were upregulated and strikingly, pharmacological inhibition of the inflammatory

response ameliorated JMML-like MPN in the zebrafish model, suggesting this may

be a first step for therapeutic intervention in human patients.

Materials and methods

Zebrafish husbandry

All procedures involving experimental animals were approved by the animal experiments committee of the Royal Netherlands Academy of Arts and Sciences (KNAW), Dierexperimenten commissie protocol HI18-0702, and performed under the local guidelines in compliance with national and European law. The following zebrafish lines were used in the study: Tübingen longfin (TL, wild type), Tg(*cd41:GFP, kdrl:mCherry-CAAX*) (Hogan et al., 2009; Lin et al., 2005), Tg*(mpx:GFP, mpeg:mCherry)* (Ellett et al., 2011; Renshaw et al., 2006)*,* TgBAC(*il1b:eGFP*)sh445 (Ogryzko et al., 2019), *ptpn11b-/-* (Bonetti et al., 2014)*prkdc-/-* (Moore et al., 2016) and the novel Shp2^{D61G} zebrafish line*.* Raising and maintenance of zebrafish was performed according to (Aleström et al., 2020; Westerfield, 2000). When required, pigmentation of embryos was blocked by adding phenylthiourea (PTU) (Sigma Aldrich, St. Louis, MO, USA, Ref: P7629) at a concentration of 0.003% (v/v) to the E3 medium at 24hpf.

Patient material

All children's samples were obtained after parents had given their written informed consent. Experiments were approved by the institutional review board of the French Institute of Health and Medical Research (INSERM) (IORG0003254) in accordance with the Helsinki declaration. Healthy children bone marrows were obtained from intrafamilial BM transplantation donors and used with the approval of the Institutional Review Board of "Hôpitaux Universitaires Paris Nord Val-de-Seine," Paris 7 University, AP-HP), (IRB: 00006477), in accordance with the Helsinki declaration. HSPCs fractions were FACS sorted according to immunophenotypic signature as previously described (Caye et al., 2019), from PTPN11^{mut} JMML (n=5) and healthy children bone marrow (n=7). Age, sex, mutations and fractions available for each sample (Hematopoietic stem cells (HSCs), multipotent progenitors (MPPs), common myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), and megakaryocyte-erythroid progenitors (MEPs)) are indicated in **Supplementary file 2**.

Generation of the Shp2^{D61G} zebrafish line

The Shp2^{D61G} zebrafish line was generated using the previously described CRISPR/Cas9-based knock-in approach (Tessadori et al., 2018). The sgRNA

targeting exon 3 of the *ptpn11a* gene (5'- GGAGACTATTACGACCTGTA-3') was

designed using the CHOP-CHOP database (http://chopchop.cbu.uib.no/), further

processed according to the previously published guidelines (Gagnon et al., 2014)

and finally transcribed using the Ambion MEGAscript T7 kit (TermoFisher Scientific,

Waltham, MA, USA, Ref: AMB13345). The sgRNA, constant oligonucleotide and

template oligonucleotide were all generated by Integrated DNA Technologies (IDT,

Coralville, IA, USA) as standard desalted oligos and template oligonucleotide was

further purified using the QIAquick Nucleotide Removal Kit (Qiagen, Hilden,

Germany, Ref: 28304). The oligonucleotide used for the homology repair is 59

nucleotides long and besides the D61G mutation, contains three additional silent

mutations in proximity of the PAM site. The sequence of template oligonucleotide is

5'-

GAGTGGCAAACTTCTCTCCACCATATAAATCGTAATAGCCTCCTGTGTTTTGAAT

CTTA-3'. Tübingen longfin wt zebrafish embryos at the one-cell-stage were injected

directly in the cell with 1 nl of the injection mixture containing 18.75 ng/ml of sgRNA,

37.5 ng/ml of template oligonucleotide and 3.6 mg/ml of Cas9 protein in 300 mM

KCl. Cas9 protein was a gift from the Niels Geijsen laboratory at the Hubrecht

Institute. The injected embryos were grown into the adulthood. F0 generation

zebrafish were outcrossed with the wt zebrafish. DNA extracted from the 12 distinct

1dpf old F1 generation embryos was screened for the correct insertion of the

template oligonucleotide. Screening was done by Sanger sequencing (Macrogen

Europe B.V., Amsterdam, The Netherland) of the 225 bp long PCR product

encompassing the genomic regions of the CRISPR target sites, which was

generated using the forward 5'-TCATCTCCTCACTAGGCGAAAT-3' and reverse

primer 5'- TATGTATGTGCTCACCTCTCGG-3'. The efficiency of the knock-in was

1.8% (1 founder zebrafish in 54 screened primary injected zebrafish). F1 generation

was then established from the F0 founder. F1 generation adults were finclipped and

sequenced for the presence of the mutation. All experiments were performed in

zebrafish embryos and adults from the F3 and F4 generation. For all of the

experiments except single cell RNA sequencing and RT-qPCR, embryos were

siblings derived from an incross of Shp2$^{D61G/wt}$ animals. After the experimental

procedure, embryos were lysed and genotyped by sequencing as described above.

Western blotting was performed as previously described (Hale & den Hertog, 2017)

510 using the Shp2 (Santa Cruz Biotechnology, Dallas, TX, USA, Ref: SC-280) and β-

511 tubulin (Merck Millipore, Burlington, MA, USA Ref: CP06) antibodies.

Phenotyping of the NS traits

Body axis lengths were measured from the tip of the head to the end of the trunk in

the bright-field images of laterally positioned embryos, larva and adults, which were

anesthetized in 0.1% MS-222. Alcian blue (Sigma Aldrich, Ref: A5268) staining was

performed as previously described (Paardekooper Overman et al., 2014), on PTU-

treated 4dpf old embryos, which were anesthetized in 0.1% MS-222 and fixed in 4%

PFA overnight. Embryos were positioned on their back in 70% glycerol in PBS and

imaged with Leica M165 FC stereomicroscope (Leica Microsystems, Wetzlar,

Germany. Analysis was performed in ImageJ. *In vivo* high-speed brightfield imaging

of the embryonic hearts from PTU-treated embryos at 5dpf, which were anesthetized

in 0.1% MS-222 and embedded in 0.3% UltraPure agarose (Thermo Fisher

Scientific, Waltham, MA, USA) prepared in E3 medium containing 16 mg/ml MS-222.

Measurements were performed at 28°C using a Leica DM IRBE inverted light

microscope (Leica Microsystems) with a Hamamatsu C9300-221 high-speed CCD

camera (Hamamatsu Photonics, Hamamatsu, Japan). Imaging was conducted at

150 frames per seconds (fps) using Hokawo 2.1 imaging software (Hamamatsu

Photonics) for a period of 10 seconds (approximately 30 cardiac cycles). Heart rate

measurements and contractility parameters were analysed using ImageJ. Volumes

were analysed using ImageJ by drawing an ellipse on top of the ventricle at end-

diastole and end-systole. Averages of three measurements per heart were

determined. End diastolic and end systolic volume (EDV/ESV) were calculated by:

$(4/3)*(\pi)*(\text{major axis}/2)*((\text{minor axis}/2)^2)$. Stroke volume (SV) by: EDV-ESV.

Ejection fraction (EF) by: (SV/EDV)*100. Cardiac output (CO) by: SV*Heart rate.

Whole mount *in situ* hybridization

PTU-treated embryos were anesthetized in 0.1% MS-222 (Sigma Aldrich, Ref:

A5040) and fixed in 4% PFA for at least 12h at 4°C. *WISH* was performed as

described in (Thisse et al., 1993)**.** Probes specific for *myl7*, *vhmc* and *ahmc* were

described in (Bonetti et al., 2014). Probes specific for *c-myb*, *l-plastin*, *pu.1*, *gata1*,

ikaros, *b-globin* and *alas-2* were described in (Choorapoikayil et al., 2014; Hu et al.,

2014)**.** Subsequently, embryos were mounted in 70% glycerol in PBS and imaged

with Leica M165 FC stereomicroscope (Leica Microsystems). Images were

processed in ImageJ (U. S. National Institutes of Health, Bethesda, MD, USA).

Abundance of the probe signal was scored as low, mild or high.

Inhibitors treatment

PTU-treated embryos were incubated with either 0.15µM of CI1040 (Sigma Aldrich,

Ref: PZ0181), 4µM LY294002 (Sigma Aldrich, Ref: L9908) or 10µM of

Dexamethasone (Sigma Aldrich, Ref: D4902) continuously from 48hpf until 5dpf in

the same medium. At 5dpf embryos were either fixed and half of the embryos was

processed for WISH using probe specific for *c-myb* and the other half using probe

specific for *l-plastin*, or snap-frozen and processed for RT-qPCR, while the live

embryos in Tg*(mpx:GFP, mpeg:mCherry)* transgenic background were imaged by

confocal microscopy

Confocal microscopy

All confocal imaging was performed on a Leica SP8 confocal microscope (Leica

Microsystems). Embryos were mounted in 0.3% agarose. Live embryos were

anesthetized in MS-222. Whole embryos were imaged using a 10X objective and z-

stack step size of $3\mu m$, while the CHT area with 20X objective and z-stack step size

of $1\mu m$. The number of CD41-GFP^{low} cells was determined by imaging the CHT of

the living 5dpf old embryos of the Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ siblings in

the Tg(*cd41:GFP, kdrl:mCherry-CAAX*) transgenic background, while the number of

CD41-GFP^{high} cells was determined by imaging whole embryos, which were fixed for

2h in 4% PFA prior to imaging. To determine the number of mpx-GFP and mpeg-

mCherry cells, whole live 5dpf old embryos of the Shp2^{wt}, Shp2$^{D61G/wt}$ and

Shp2$^{D61G/D61G}$ line in the Tg*(mpx:GFP, mpeg:mCherry)* transgenic background were

imaged. Imaris V9.3.1 (Bitplane, Zurich, Switzerland) was used to reconstruct 3D

images and count individual GFP and/or mCherry positive cells.

Phosphorylated Histone 3 (pHis3) staining

PTU-treated 5dpf old Shp2^{D61G} embryos in the Tg(*cd41:GFP, kdrl:mCherry-CAAX*)

transgenic background were fixed in 2% PFA overnight and stained as described in

(Choorapoikayil et al., 2012). Primary pHis3 antibody (1:500 in blocking buffer,

Abcam, Cambridge, UK, Ref: ab5176) and secondary GFP antibody (1:200 in

blocking buffer, Aves Labs Inc. Tigard, OR, USA, GFP-1010) were used. Embryos

were mounted in 0.3% agarose, their CHT was imaged using the SP8 confocal

microscope and 3D images were subsequently reconstructed using Imaris.

Acridine orange staining

PTU-treated embryos at 5dpf were incubated in 5µg/ml of Acridine orange (Sigma Aldrich, Ref: A6014) in E3 medium, for 20 minutes at room temperature. They were then washed 5 times for 5 minutes in E3 medium, anesthetized in MS-222 and mounted in 0.3% agarose. Whole embryos were imaged with SP8 confocal microscope and 3D images were reconstructed using Imaris.

Colony forming assay

The CD41-GFP^{low} cell population isolated from CHTs of Shp2^{wt}, Shp2$^{D61G/wt}$ embryos at 5dpf was FACS sorted. 250 µl of solution containing 2 500 cells, media prepared as described in (Svoboda et al., 2016)**,** and 100 ng/ml of granulocyte colony stimulating factor a (Gcsfa, gift from the Petr Bartunek lab, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic v.v.i. Prague) was plated per well of a 96 well plate in a triplicate. Cells were grown in humidified incubators at 32°C, 5% CO_2. After 6 days colonies were imaged and counted using the EVOS microscope (Termo Fisher Scientific).

Quantitative reverse transcription PCR (RT-qPCR)

Zebrafish siblings of either Shp2^{wt} or Shp2$^{D61G/D61G}$ genotypes were crossed to generate embryos of Shp2^{wt} and Shp2$^{D61G/D61G}$ genotype. At 5dpf, 5 embryos of the same condition were pooled and snap frozen in liquid nitrogen. Total RNA was extracted from embryos using the TRIzol reagent according to the manufacturer's instructions (Thermo Fisher Scientific, Invitrogen, Ref: 15596018). cDNA synthesis was performed from 800 ng of RNA using the SuperScript® III First-Strand kit (Thermo Fisher Scientific, Invitrogen, Ref: 12574018). RT-qPCR was performed with an CFX Connect Real-Time system (Bio-Rad Laboratories Inc., Hercules, CA, USA) using FastStart Universal SYBR Green Master (ROX) (Roche, Basel, Switzerland) and 1:20 dilution of cDNA. Reaction mixtures were incubated for 10 min at 95°C, followed by 42 cycles of product amplification (15 seconds at 95°C and 1 minute at 58°C). For each condition 4 samples were used in duplicate. Gene expression was normalized against the expression of *ef1a* for each mRNA. The following primers were used: *ef1a* forward, 5'-GAGAAGTTCGAGAAGGAAGC-3'; *ef1a* reverse, 5'-CGTAGTATTTGCTGGTCTCG-3'; *tnfa* forward, 5'-AGACCTTAGACTGGAGAGATGAC-3'; *tnfa* reverse, 5'-CAAAGACACCTGGCTGTAGAC-3'; *gcsfb* forward, 5'-

AGAGAACCTACTGAACGACCT-3'; *gcsfb* reverse, 5'-

CTTGAACTGGCTGAGTGGAG-3'; *il1b* forward, 5'-

GAACAGAATGAAGCACATCAAACC-3'; *il1b* reverse, 5'-

ACGGCACTGAATCCACCAC-3'.

Transplantation experiments

Zebrafish kidney marrow transplantation were performed as previously described

(Moore et al., 2016; Tang et al., 2014). In short, tissues were isolated from donor

Shp2$^{D61G/wt}$ or wild type animals in the Tg(*mpx:GFP, mpeg:mCherry*) background

following Tricaine (Western Chemical, Brussels, Belgium) overdose. Excised tissues

from dissected fish are placed into 500 μl of 0.9x PBS + 5% FBS on a 10-cm Petri

dish. Single-cell suspensions were obtained by maceration with a razor blade,

followed by manual pipetting to disassociate cell clumps. Cells were filtered through

a 40-μm Falcon cell strainer, centrifuged at 1,000 *g* for 10 min, and resuspended to

the 2 x 10^7 cells/ml. 5-μl suspension containing 10^5 kidney marrow cells were

injected into the peritoneal cavity of each recipient fish using a 26s Hamilton 80366

syringe. Cellular engraftment was assessed at 0, 7, 14, 28 dpt by epifluorescence

microscopy.

Isolation of CD41-GFP^{low} cell population and single-cell RNA sequencing

Zebrafish siblings of either Shp2^{wt} or Shp2$^{D61G/D61G}$ genotypes were crossed to

generate embryos of Shp2^{wt}, Shp2$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ genotype. From 24hpf

onwards embryos were grown in PTU-containing medium. The CHTs of

approximately 50 randomly selected Shp2^{wt}, Shpt$^{D61G/wt}$ and Shp2$^{D61G/D61G}$ embryos

in Tg(*cd41:GFP, kdrl:mCherry-CAAX*) transgenic background at 5dpf were dissected

and CHTs of the same genotype were pooled in Leibovitz-medium (Thermo Fisher

Scientific, Gibco, Ref: 11415049). After washing with PBS0 the CHTs were

dissociated with TryplE (Thermo Fisher Scientific, Gibco, Ref: 12605036) for 45

minutes at 32°C. The resulting cell suspension was washed with PBS0, resuspended

in PBS0 supplemented with 2mM EDTA, 2% FCS and 0.5μg/ml DAPI (Sigma

Aldrich, Ref: D9542) and passed through a 40μm Falcon cell strainer. DAPI staining

was used to exclude dead cells. Cells with CD41-GFP^{low} positive signal were

subjected to fluorescence-activated cell sorting (FACS) with an influx cytometer (BD

Biosciences, San Jose, CA, USA). Single-cell RNA sequencing was performed

according to an adapted version of the SORT-seq (Muraro et al., 2016) with adapted

primers described in (Van Den Brink et al., 2017). In short, single cells were FACS

sorted, as described above, on 384-well plates containing 384 primers and Mineral oil (Sigma Aldrich). After sorting, plates were snap-frozen on dry ice and stored at -80°C. For amplification cells were heat-lysed at 65°C followed by cDNA synthesis using the CEL-seq2 (Hashimshony et al., 2016) and robotic liquid handling platforms. After the second strand cDNA synthesis, the barcoded material was pooled into libraries of 384 cells and amplified using *in vitro* transcription. Following amplification, the rest of the CEL-seq2 protocol was followed for preparation of the amplified cDNA library, using TruSeq small RNA primers (Illumina, San Diego, CA, USA). The DNA library was paired-end sequenced on an Illumina Nextseq™ 500 (Illumina), high output, with a 1x75 bp Illumina kit (R1:26 cycles, index read: 6 cycles, R2:60 cycles).

Data analysis of single-cell RNA sequencing

During sequencing, Read1 was assigned 26 base pairs and was used for identification of the Ilumina library barcode, cell barcode and unique molecular identifier. Read2 was assigned 60 base pairs and used to map to the reference transcriptome of Zv9 Danio rerio. Data was demultiplexed as described in (Grün et al., 2014). Single cell transcriptomics analysis was done using the RaceID3 algorithm (Herman et al., 2018), following an adapted version of the RaceID manual (https://cran.r-project.org/web/packages/RaceID/vignettes/RaceID.html) using R-3.5.2. In total 768 cells per genotype were sequenced for the datasets. After removing cells with less than 1000 UMIs and only keeping genes that were detected with at least 3 UMIs in 1 cell, 439 wt, 384 D61G/wt and 543 D61G/D61G cells were left for further analysis. Batch effects observed for plates which were prepared on different days was removed using the scran function. 4 major clusters and 5 minor clusters were identified. The minor clusters contained 130 cells in total and were excluded from further analysis for statistical reasons. Differential gene expression analysis was done as described in (Muraro et al., 2016) with an adapted version of the DESseq2 (Love et al., 2014). GO term enrichment analysis for differentially expressed genes of each major cluster was performed using the DAVID Bioinformatics Resources 6.8 (https://david.ncifcrf.gov/). Trajectory inference and pseudotime analysis were done using Monocle3 (v1.0.0). The data was subset to include the major cell types; HSC-like cells, thrombocyte and erythrocyte progenitors, early myeloid progenitors, and monocyte/macrophage progenitors. The normalized counts, tSNE coordinates and clusters generated by RaceID3 were used for trajectory inference. To investigate the potential lineage differentiation path, the

HSC-like cluster (center) was then selected as root for pseudotime analysis and
used to order cells in pseudotime.

RNA sequencing and differential gene expression analysis of the patient
material
Libraries were prepared with TruSeq® Stranded Total RNASample preparation kit
(Illumina) according to supplier's recommendations. Briefly, the ribosomal RNA
fraction was removed from 1µg of total RNA using the Ribo-Zero™ Gold Kit (Illumina).
Fragmentation was then achieved using divalent cations under elevated temperature
to obtain approximately 300bp pieces. Double strand cDNA synthesis was performed
using reverse transcriptase and random primers, Illumina adapters were ligated and
cDNA library was PCR amplified for sequencing. Paired-end 75b sequencing was then
carried out on a HiSeq4000 (Illumina). Quality of reads was assessed for each sample
using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). A subset
of 500,000 reads from each Fastq file was aligned to the reference human genome
hg19/GRCh37 with tophat2 to determine insert sizes with Picard. Full Fastq files were
aligned to the reference human genome hg19/GRCh37 with tophat2 (-p 24 -r 150 -g 2
--library-type fr-firststrand) (Kim et al., 2013). We removed reads mapping to multiple
locations. STAR was used to obtain the number of reads associated with each gene
in the Gencode v26lift37 annotation (restricted to protein-coding genes, antisense, and
lincRNAs). Raw counts for each sample were imported into R statistical software using
the Bioconductor DESeq2 package. Extracted count matrix was normalized for library
size and coding length of genes to compute TPM expression levels. Differential gene
expression analysis was performed using the Bioconductor limma package and the
voom transformation. To improve the statistical power of the analysis, only genes
expressed in at least one sample (TPM >0.3) were considered. A qval threshold of <
0.05 and a minimum fold change of 1.2 were used to define differentially expressed
genes. Due to the imbalance between male and female samples, sex differences were
adjusted with the function model.matrix from the stats package. RNAseq data analysis
was performed with Galileo® v1.4.4, an interactive R shiny application.
Representations of the gene expression levels were performed with the library ggplot2
and R 4.0.2.
Pathway enrichment analysis (GSEA) and Principal component analysis (PCA)

Gene set enrichment analysis was performed by clusterProfiler::GSEA function using

the fgsea algorithm. Gene list from the differential analysis was ordered by decreasing

log2 (fold change). Hallmark classes Gene sets from the MSigDB v7.2 database were

selected keeping only gene sets defined by 10-500 genes. The p-values were adjusted

by the Benjamini-Hochberg (FDR) procedure. The custom zebrafish signature was

built from the human orthologous genes of the 100 most overexpressed zebrafish

genes based on the log2 (Fold Change) derived from the monocyte/macrophage

progenitor cluster of the zebrafish HSPCs single cell sequencing dataset. The

Bioconductor edgeR package was used to import raw counts into R, and compute

normalized log2 CPM (counts per millions of mapped reads) using the TMM (weighted

trimmed mean of M-values) as normalization procedure. The normalized expression

matrix from the 100 most overexpressed genes (based on log2FC in the zebrafish

dataset) was used to classify the samples according to their gene expression patterns

using principal component analysis (PCA). PCA was performed by FactoMineR::PCA

function with "ncp = 10, scale.unit = FALSE" parameters.

Statistical analysis

Data was plotted in GraphPad Prism 7.05 (GraphPad Software Inc., San Diego, CA,

USA), except for the violin plots of gene expression, which were plotted in R using

ggplot2(Wickham, 2009). Statistical difference analysis was performed using the

one-way ANOVA supplemented by Tukey's HSD test in GraphPad Prism 7.05,

except for the gene expression differences in single cell RNA sequencing data,

where T-test was performed in Rstudio 1.1.463 (Rstudio, Boston, MA, USA), and the

treatment WISH experiments, where Chi-squared test was performed in GraphPad

Prism 7.05. Significant difference was considered when $p < 0.05$ (*$p < 0.05$, **$p < 0.01$,

***$p < 0.001$, NS=non significant).

Author Contributions

MS Conceptualization, Methodology, Formal analysis, Investigation, Data Curation, Writing - Original Draft, Visualization, **SBF** Investigation, Formal analysis, Data Curation, Methodology, Writing - Review & Editing, **FP** Investigation, Formal Analysis, Methodology, Writing - Review Editing, **CY, QY** Investigation- performed transplantation experiments, Data Curation, Formal analysis, Methodology, Writing - Review & Editing, **MS** Investigation, Formal Analysis, Methodology, **SMK** Investigation- provided assistance with heart function analysis, Methodology, Resources, Writing - Review & Editing, **PA** Investigation, Formal analysis, **JB** Conceptualization, Supervision, Writing - Review & Editing, **DML** Conceptualization, Supervision, Writing - Review & Editing, **HC** Conceptualization, Supervision, Writing - Review & Editing, **JDH** Conceptualization, Supervision, Funding acquisition, Project administration, Writing - Original Draft

Acknowledgements

We thank the laboratory of Niels Geijsen (Hubrecht Institute) for providing us with Cas9 protein, Petr Bartunek and Olga Machanova (Institute of Molecular Genetics, Academy of Sciences of the Czech Republic v.v.i. Prague) and Geert Wiegertjes (University Wageningen) for cytokines and carp serum, Stefan van der Elst for assistance with FACS sorting, Hubrecht Institute animal caretakers for animal support and Single Cell Discoveries and Chloé Baron for support with single cell RNA sequencing. This work was supported by E-Rare grant NSEuroNet (JdH and HC), EJPRD grant NSEuroNet (JdH and HC), NIH grants R01CA211734 (D.M.L) and R24OD016761 (D.M.L), the MGH Research Scholar Award (D.M.L.) and Alex Lemonade Stand Foundation (C.Y.).

759 **Competing Interests:**

760 The authors declare no competing interests.

References

Aleström, P., D'Angelo, L., Midtlyng, P. J., Schorderet, D. F., Schulte-Merker, S.,

    Sohm, F., & Warner, S. (2020). Zebrafish: Housing and husbandry

    recommendations. *Laboratory Animals*, *54*(3), 213–224.

    https://doi.org/10.1177/0023677219869037

Araki, T., Chan, G., Newbigging, S., Morikawa, L., Bronson, R., & Neel, B. G. (2009).

    Noonan syndrome cardiac defects are caused by PTPN11 acting in

    endocardium to enhance endocardial-mesenchymal transformation.

    Proceedings of the National Academy of Sciences of the United States of

    America, *106*(12), 4736–4741. https://doi.org/10.1073/pnas.0810053106

Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang,

    W., Pao, L. I., Gilliland, D. G., Epstein, J. A., & Neel, B. G. (2004). Mouse model

    of Noonan syndrome reveals cell type- and gene dosage-dependent effects of

    Ptpn11 mutation. *Nature Medicine*, *10*(8), 849–857.

    https://doi.org/10.1038/nm1084

Arranz, L., Arriero, M. del M., & Villatoro, A. (2017). Interleukin-1β as emerging

    therapeutic target in hematological malignancies and potentially in their

    complications. In *Blood Reviews* (Vol. 31, Issue 5, pp. 306–317). Churchill

    Livingstone. https://doi.org/10.1016/j.blre.2017.05.001

Bagby, G. C., Dinarello, C. A., Neerhout, R. C., Ridgway, D., & McCall, E. (1988).

    Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic

    leukemia of the juvenile type. *Journal of Clinical Investigation*, *82*(4), 1430–

    1436. https://doi.org/10.1172/JCI113748

Behnert, A., Meyer, J., Parsa, J.-Y., Hechmer, A., Loh, M. L., Olshen, A., Smith, A. J.

    de, & Stieglitz, E. (2021). Exploring the genetic and epigenetic origins of juvenile

myelomonocytic leukemia using newborn screening samples. *Leukemia 2021*, 1–4. https://doi.org/10.1038/s41375-021-01331-0

Bonetti, M., Rodriguez-Martinez, V., Overman, J. P., Overvoorde, J., Van Eekelen, M., Jopling, C., & Den Hertog, J. (2014). Distinct and overlapping functions of ptpn11 genes in zebrafish development. *PLoS ONE*, *9*(4), e94884. https://doi.org/10.1371/journal.pone.0094884

Caye, A., Rouault-Pierre, K., Strullu, M., Lainey, E., Abarrategi, A., Fenneteau, O., Arfeuille, C., Osman, J., Cassinat, B., Pereira, S., Anjos-Afonso, F., Currie, E., Ariza-McNaughton, L., Barlogis, V., Dalle, J. H., Baruchel, A., Chomienne, C., Cavé, H., & Bonnet, D. (2019). Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. *Leukemia*, 1–11. https://doi.org/10.1038/s41375-019-0662-y

Caye, A., Strullu, M., Guidez, F., Cassinat, B., Gazal, S., Fenneteau, O., Lainey, E., Nouri, K., Nakhaei-Rad, S., Dvorsky, R., Lachenaud, J., Pereira, S., Vivent, J., Verger, E., Vidaud, D., Galambrun, C., Picard, C., Petit, A., Contet, A., … Cavé, H. (2015). Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. *Nature Genetics 2015 47:11*, *47*(11), 1334–1340. https://doi.org/10.1038/ng.3420

Chan, G., Kalaitzidis, D., Usenko, T., Kutok, J. L., Yang, W., Mohi, M. G., & Neel, B. G. (2009). Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. *Blood*, *113*(18), 4414–4424. https://doi.org/10.1182/BLOOD-2008-10-182626

Choorapoikayil, S., Kers, R., Herbomel, P., Kissa, K., & den Hertog, J. (2014). Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish. *Blood*, *123*(2), 184–190.

811 https://doi.org/10.1182/BLOOD-2013-05-501544

812 Choorapoikayil, S., Kuiper, R. V, de Bruin, A., & den Hertog, J. (2012).

813 Haploinsufficiency of the genes encoding the tumor suppressor Pten

814 predisposes zebrafish to hemangiosarcoma. *Disease Models & Mechanisms*,

815 *5*(2), 241–247. https://doi.org/10.1242/dmm.008326

816 Craver, B. M., El Alaoui, K., Scherber, R. M., & Fleischman, A. G. (2018). The critical

817 role of inflammation in the pathogenesis and progression of myeloid

818 malignancies. In *Cancers* (Vol. 10, Issue 4). MDPI AG.

819 https://doi.org/10.3390/cancers10040104

820 de Pater, E., & Trompouki, E. (2018). Bloody Zebrafish: Novel Methods in Normal

821 and Malignant Hematopoiesis. *Frontiers in Cell and Developmental Biology*, *6*,

822 124. https://doi.org/10.3389/fcell.2018.00124

823 Dong, L., Yu, W. M., Zheng, H., Loh, M. L., Bunting, S. T., Pauly, M., Huang, G.,

824 Zhou, M., Broxmeyer, H. E., Scadden, D. T., & Qu, C. K. (2016).

825 Leukaemogenic effects of Ptpn11 activating mutations in the stem cell

826 microenvironment. *Nature*, *539*(7628), 304–308.

827 https://doi.org/10.1038/nature20131

828 Ehrchen, J. M., Roth, J., & Barczyk-Kahlert, K. (2019). More Than Suppression:

829 Glucocorticoid Action on Monocytes and Macrophages. *Frontiers in*

830 *Immunology*, *0*(AUG), 2028. https://doi.org/10.3389/FIMMU.2019.02028

831 Ellett, F., Pase, L., Hayman, J. W., Andrianopoulos, A., & Lieschke, G. J. (2011).

832 mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish.

833 *Blood*, *117*(4), e49. https://doi.org/10.1182/blood-2010-10-314120

834 Freedman, M. H., Cohen, A., Grunberger, T., Bunin, N., Luddy, R. E., Saunders, E.

835 F., Shahidi, N., Lau, A., & Estrov, Z. (1992). Central role of tumour necrosis

factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic

myelogenous leukaemia. *British Journal of Haematology*, *80*(1), 40–48.

https://doi.org/10.1111/j.1365-2141.1992.tb06398.x

Gagnon, J. A., Valen, E., Thyme, S. B., Huang, P., Akhmetova, L., Ahkmetova, L.,

Pauli, A., Montague, T. G., Zimmerman, S., Richter, C., & Schier, A. F. (2014).

Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and

large-scale assessment of single-guide RNAs. *PloS One*, *9*(5), e98186.

https://doi.org/10.1371/journal.pone.0098186

Gore, A. V., Pillay, L. M., Venero Galanternik, M., & Weinstein, B. M. (2018). The

zebrafish: A fintastic model for hematopoietic development and disease. *Wiley*

Interdisciplinary Reviews: Developmental Biology, *7*(3), e312.

https://doi.org/10.1002/wdev.312

Grün, D., Kester, L., & Van Oudenaarden, A. (2014). Validation of noise models for

single-cell transcriptomics. *Nature Methods*, *11*(6), 637–640.

https://doi.org/10.1038/nmeth.2930

Hale, A. J., & den Hertog, J. (2017). Shp2–Mitogen-Activated Protein Kinase

Signaling Drives Proliferation during Zebrafish Embryo Caudal Fin Fold

Regeneration. *Molecular and Cellular Biology*, *38*(4).

https://doi.org/10.1128/mcb.00515-17

Hashimshony, T., Senderovich, N., Avital, G., Klochendler, A., de Leeuw, Y., Anavy,

L., Gennert, D., Li, S., Livak, K. J., Rozenblatt-Rosen, O., Dor, Y., Regev, A., &

Yanai, I. (2016). CEL-Seq2: Sensitive highly-multiplexed single-cell RNA-Seq.

Genome Biology, *17*(1), 77. https://doi.org/10.1186/s13059-016-0938-8

Herman, J. S., Sagar, & Grün, D. (2018). FateID infers cell fate bias in multipotent

progenitors from single-cell RNA-seq data. *Nature Methods*, *15*(5), 379–386.

https://doi.org/10.1038/nmeth.4662

Hogan, B. M., Bos, F. L., Bussmann, J., Witte, M., Chi, N. C., Duckers, H. J., &

Schulte-Merker, S. (2009). Ccbe1 is required for embryonic lymphangiogenesis

and venous sprouting. *Nature Genetics*, *41*(4), 396–398.

https://doi.org/10.1038/ng.321

Hu, B., Zhang, W., Feng, X., Ji, W., Xie, X., & Xiao, W. (2014). Zebrafish eaf1

suppresses foxo3b expression to modulate transcriptional activity of gata1 and

spi1 in primitive hematopoiesis. *Developmental Biology*, *388*(1), 81–93.

https://doi.org/10.1016/j.ydbio.2014.01.005

Jopling, C., Van Geemen, D., & Den Hertog, J. (2007). Shp2 knockdown and

noonan/LEOPARD mutant Shp2-induced gastrulation defects. *PLoS Genetics*,

3(12), e225. https://doi.org/10.1371/journal.pgen.0030225

Kratz, C. P., Niemeyer, C. M., Castleberry, R. P., Cetin, M., Bergsträsser, E.,

Emanuel, P. D., Hasle, H., Kardos, G., Klein, C., Kojima, S., Stary, J., Trebo, M.,

Zecca, M., Gelb, B. D., Tartaglia, M., & Loh, M. L. (2005). The mutational

spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan

syndrome/myeloproliferative disease. *Blood*, *106*(6), 2183–2185.

https://doi.org/10.1182/blood-2005-02-0531

Lin, H. F., Traver, D., Zhu, H., Dooley, K., Paw, B. H., Zon, L. I., & Handin, R. I.

(2005). Analysis of thrombocyte development in CD41-GFP transgenic

zebrafish. *Blood*, *106*(12), 3803–3810. https://doi.org/10.1182/blood-2005-01-

0179

Louka, E., Povinelli, B., Rodriguez-Meira, A., Buck, G., Wen, W. X., Wang, G.,

Sousos, N., Ashley, N., Hamblin, A., Booth, C. A. G., Roy, A., Elliott, N.,

Iskander, D., De La Fuente, J., Fordham, N., O'Byrne, S., Inglott, S., Norfo, R.,

Salio, M., … Mead, A. J. (2021). Heterogeneous disease-propagating stem cells

in juvenile myelomonocytic leukemia. *Journal of Experimental Medicine*, *218*(2).

https://doi.org/10.1084/JEM.20180853

Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change

and dispersion for RNA-seq data with DESeq2. *Genome Biology*, *15*(12), 550.

https://doi.org/10.1186/s13059-014-0550-8

Moore, J. C., Tang, Q., Yordán, N. T., Moore, F. E., Garcia, E. G., Lobbardi, R.,

Ramakrishnan, A., Marvin, D. L., Anselmo, A., Sadreyev, R. I., & Langenau, D.

M. (2016). Single-cell imaging of normal and malignant cell engraftment into

optically clear prkdc-null scid zebrafish. *Journal of Experimental Medicine*,

213(12), 2575–2589. https://doi.org/10.1084/jem.20160378

Mulero-Navarro, S., Sevilla, A., Roman, A. C., Lee, D.-F., D'Souza, S. L., Pardo, S.,

Riess, I., Su, J., Cohen, N., Schaniel, C., Rodriguez, N. A., Baccarini, A., Brown,

B. D., Cavé, H., Caye, A., Strullu, M., Yalcin, S., Park, C. Y., Dhandapany, P. S.,

… Gelb, B. D. (2015). Myeloid Dysregulation in a Human Induced Pluripotent

Stem Cell Model of PTPN11 -Associated Juvenile Myelomonocytic Leukemia.

Cell Reports, *13*(3), 504–515. https://doi.org/10.1016/j.celrep.2015.09.019

Muraro, M. J., Dharmadhikari, G., Grün, D., Groen, N., Dielen, T., Jansen, E., van

Gurp, L., Engelse, M. A., Carlotti, F., de Koning, E. J. P., & van Oudenaarden,

A. (2016). A Single-Cell Transcriptome Atlas of the Human Pancreas. *Cell*

Systems, *3*(4), 385-394.e3. https://doi.org/10.1016/j.cels.2016.09.002

Niihori, T., Nagai, K., Fujita, A., Ohashi, H., Okamoto, N., Okada, S., Harada, A.,

Kihara, H., Arbogast, T., Funayama, R., Shirota, M., Nakayama, K., Abe, T.,

Inoue, S. ichi, Tsai, I. C., Matsumoto, N., Davis, E. E., Katsanis, N., & Aoki, Y.

(2019). Germline-Activating RRAS2 Mutations Cause Noonan Syndrome.

American Journal of Human Genetics, *104*(6), 1233–1240.

https://doi.org/10.1016/j.ajhg.2019.04.014

Ogryzko, N. V., Lewis, A., Wilson, H. L., Meijer, A. H., Renshaw, S. A., & Elks, P. M.

(2019). Hif-1α–Induced Expression of Il-1β Protects against Mycobacterial

Infection in Zebrafish. *The Journal of Immunology*, *202*(2), 494–502.

https://doi.org/10.4049/JIMMUNOL.1801139

Oltova, J., Svoboda, O., & Bartunek, P. (2018). Hematopoietic Cytokine Gene

Duplication in Zebrafish Erythroid and Myeloid Lineages. *Frontiers in Cell and Developmental Biology*, *6*(DEC), 174.

https://doi.org/10.3389/FCELL.2018.00174

Paardekooper Overman, J., Yi, J.-S., Bonetti, M., Soulsby, M., Preisinger, C.,

Stokes, M. P., Hui, L., Silva, J. C., Overvoorde, J., Giansanti, P., Heck, A. J. R.,

Kontaridis, M. I., Den Hertog, J., & Bennett, A. M. (2014). PZR Coordinates

Shp2 Noonan and LEOPARD Syndrome Signaling in Zebrafish and Mice.

Molecular and Cellular Biology, *34*(15), 2874–2889.

https://doi.org/10.1128/MCB.00135-14

Rauen, K. A. (2013). The RASopathies. *Annu. Rev. Genomics Hum. Genet*, *14*,

355–369. https://doi.org/10.1146/annurev-genom-091212-153523

Renshaw, S. A., Loynes, C. A., Trushell, D. M. I., Elworthy, S., Ingham, P. W., &

Whyte, M. K. B. (2006). A transgenic zebrafish model of neutrophilic

inflammation. *Blood*, *108*(13), 3976–3978. https://doi.org/10.1182/blood-2006-

05-024075

Runtuwene, V., van Eekelen, M., Overvoorde, J., Rehmann, H., Yntema, H. G.,

Nillesen, W. M., van Haeringen, A., van der Burgt, I., Burgering, B., & den

Hertog, J. (2011). Noonan syndrome gain-of-function mutations in NRAS cause

zebrafish gastrulation defects. *Disease Models & Mechanisms*, *4*(3), 393–399.

https://doi.org/10.1242/dmm.007112

Stachura, D. L., Svoboda, O., Campbell, C. A., Espín-Palazón, R., Lau, R. P., Zon,
L. I., Bartůněk, P., & Traver, D. (2013). The zebrafish granulocyte colony-
stimulating factors (Gcsfs): 2 paralogous cytokines and their roles in
hematopoietic development and maintenance. *Blood*, *122*(24), 3918.
https://doi.org/10.1182/BLOOD-2012-12-475392

Strullu, M., Caye, A., Lachenaud, J., Cassinat, B., Gazal, S., Fenneteau, O.,
Pouvreau, N., Pereira, S., Baumann, C., Contet, A., Sirvent, N., Méchinaud, F.,
Guellec, I., Adjaoud, D., Paillard, C., Alberti, C., Zenker, M., Chomienne, C.,
Bertrand, Y., … Cavé, H. (2014). Juvenile myelomonocytic leukaemia and
Noonan syndrome. *Journal of Medical Genetics*, *51*(10), 689–697.
https://doi.org/10.1136/jmedgenet-2014-102611

Svoboda, O., Stachura, D. L., MacHonova, O., Zon, L. I., Traver, D., & Bartunek, P.
(2016). Ex vivo tools for the clonal analysis of zebrafish hematopoiesis. *Nature*
Protocols, *11*(5), 1007–1020. https://doi.org/10.1038/nprot.2016.053

Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015). SHP2 sails
from physiology to pathology. In *European Journal of Medical Genetics* (Vol. 58,
Issue 10, pp. 509–525). https://doi.org/10.1016/j.ejmg.2015.08.005

Tajan, M., Paccoud, R., Branka, S., Edouard, T., & Yart, A. (2018). The RASopathy
Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
Endocrine Reviews, *39*(5), 676–700. https://doi.org/10.1210/er.2017-00232

Tang, Q., Abdelfattah, N. S., Blackburn, J. S., Moore, J. C., Martinez, S. A., Moore,
F. E., Lobbardi, R., Tenente, I. M., Ignatius, M. S., Berman, J. N., Liwski, R. S.,
Houvras, Y., & Langenau, D. M. (2014). Optimized cell transplantation using
adult rag2 mutant zebrafsh. *Nature Methods*, *11*(8), 821–824.
https://doi.org/10.1038/nmeth.3031

Tarnawsky, S. P., Yoshimoto, M., Deng, L., Chan, R. J., & Yoder, M. C. (2017). Yolk

Sac Erythromyeloid Progenitors Expressing Gain Of Function PTPN11 Have
Functional Features Of JMML But Are Not Sufficient To Cause Disease In Mice.
Developmental Dynamics : An Official Publication of the American Association of
Anatomists, *246*(12), 1001. https://doi.org/10.1002/DVDY.24598

Tarnawsky, S. P., Yu, W.-M., Qu, C.-K., Chan, R. J., & Yoder, M. C. (2018).
Hematopoietic-restricted Ptpn11E76K reveals indolent MPN progression in
mice. *Oncotarget*, *9*(31), 21831. https://doi.org/10.18632/ONCOTARGET.25073

Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H.,
Van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., Kalidas, K., Patton, M. A.,
Kucherlapati, R. S., & Gelb, B. D. (2001). Mutations in PTPN11, encoding the
protein tyrosine phosphatase SHP-2, cause Noonan syndrome. *Nature
Genetics*, *29*(4), 465–468. https://doi.org/10.1038/ng772

Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen,
K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003). Somatic mutations in PTPN11 in
juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute
myeloid leukemia. *Nature Genetics*, *34*(2), 148–150.
https://doi.org/10.1038/ng1156

Tessadori, F., Roessler, H. I., Savelberg, S. M. C., Chocron, S., Kamel, S. M.,
Duran, K. J., Van Haelst, M. M., Van Haaften, G., & Bakkers, J. (2018). Effective
CRISPR/Cas9-based nucleotide editing in zebrafish to model human genetic
cardiovascular disorders. *Disease Models and Mechanisms*, *11*(10).
https://doi.org/10.1242/dmm.035469

Tessadori, F., van Weerd, J. H., Burkhard, S. B., Verkerk, A. O., de Pater, E.,
Boukens, B. J., Vink, A., Christoffels, V. M., & Bakkers, J. (2012). Identification
and Functional Characterization of Cardiac Pacemaker Cells in Zebrafish. *PLoS*

ONE, *7*(10), e47644. https://doi.org/10.1371/journal.pone.0047644

Thisse, C., Thisse, B., Schilling, T. F., & Postlethwait, J. H. (1993). Structure of the

zebrafish snail1 gene and its expression in wild-type, spadetail and no tail

mutant embryos. *Development*, *119*(4).

Van Den Brink, S. C., Sage, F., Vértesy, Á., Spanjaard, B., Peterson-Maduro, J.,

Baron, C. S., Robin, C., & Van Oudenaarden, A. (2017). Single-cell sequencing

reveals dissociation-induced gene expression in tissue subpopulations. In

Nature Methods (Vol. 14, Issue 10, pp. 935–936). Nature Publishing Group.

https://doi.org/10.1038/nmeth.4437

Westerfield, M. (2000). *The Zebrafish Book: A Guide for the Laboratory Use of*

Zebrafish (Danio Rerio) (4th ed.). University of Oregon Press.

Wickham, H. (2009). *ggplot2: Elegant Graphics for Data Analysis*. Springer

International Publishing. https://ggplot2.tidyverse.org.

Xie, Y., Meijer, A. H., & Schaaf, M. J. M. (2021). Modeling Inflammation in Zebrafish

for the Development of Anti-inflammatory Drugs. *Frontiers in Cell and*

Developmental Biology, *8*. https://doi.org/10.3389/FCELL.2020.620984

Xu, D., Liu, X., Yu, W. M., Meyerson, H. J., Guo, C., Gerson, S. L., & Qu, C. K.

(2011). Non-lineage/stage-restricted effects of a gain-of-function mutation in

tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of

hematopoietic cells. *Journal of Experimental Medicine*, *208*(10), 1977–1988.

https://doi.org/10.1084/jem.20110450

1010